ADOCIA Reports Second Quarter 2026 Financial Results and Provides a Business Update
ADOCIA financed through Q2 2027 via €6M Vester shareholder loan; BioChaperone® Lispro passes Phase 3 (1,040 type-2 patients, China filing pending). Multi-pharma consolidation signals: Sanofi exits, others enter discussions—tight capital runway amplifies acquisition risk.
ADOCIA Reports Second Quarter 2026 Financial Results and Provides a Business Update
Cash position of €9.7 million as of June 30, 2026
Shareholder loan agreement signed with Vester Finance in April 2026, securing a cash runway until the beginning of Q2 2027
BioChaperone® feasibility studies with positive results enabling to engage in discussions for the next steps with large pharmaceutical companies
Regulatory News:
ADOCIA Announces Half-Year Report on Adocia’s Liquidity Agreement with Kepler Capital Markets
ABIONYX Pharma Provides an Update on Its Operations and Cash Position for the First Quarter of 2026
ADOCIA Confirms its Eligibility for the PEA‑PME Scheme
Acadia Healthcare Announces Date for Second Quarter 2026 Earnings ReleaseAcadia Healthcare Company, Inc. (NASDAQ: ACHC) today…
Aethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate Update
Number of Shares and Voting Rights of ADOCIA as of June 30, 2026
